Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
RECRUITING
Clinical Phase
PHASE1/PHASE2
Total Enrollment
33 participants
Study Classification
INTERVENTIONAL
Study Start Date
2023-04-12
Study Completion Date
2030-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This is a two-step, multicenter, Phase I/II study including an open-label dose-escalation phase (Step 1) and a three-arm, controlled, double-masked, randomized extension phase (Step 2), in subjects with advanced RCD due to a mutation in the RHO, PDE6A, or PDE6B gene.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Safety and Tolerability Study of Gene Editing Drug ZVS203e in Participants With Retinitis Pigmentosa
NCT05805007
Retinitis Pigmentosa
RECRUITING
EARLY_PHASE1
Safety and Efficacy Study in Patients With Retinitis Pigmentosa Due to Mutations in PDE6B Gene
NCT03328130
Retinitis Pigmentosa
TERMINATED
PHASE1/PHASE2
A Study to Evaluate the Safety and Clinical Response of Subretinal Administration of CNTO 2476 in Participants With Geographic Atrophy
NCT02659098
Visual Acuity
Geographic Atrophy
Macular Degeneration
COMPLETED
PHASE2
Safety and Efficacy of ZVS203e in the Treatment of Retinitis Pigmentosa Caused by RHO Gene Mutation
NCT06952842
Retinitis Pigmentosa
NOT_YET_RECRUITING
PHASE1/PHASE2
Safety and Tolerability of hRPC in Retinitis Pigmentosa
NCT02464436
Retinitis Pigmentosa
UNKNOWN
PHASE1/PHASE2
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Retinitis Pigmentosa
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
Phase I/II study including an open-label dose-escalation phase (Step 1) and a three-arm, controlled, double-masked, randomized extension phase (Step 2)
Primary Study Purpose
TREATMENT
Blinding Strategy
QUADRUPLE
Participants
Caregivers
Investigators
Outcome Assessors
Phase I/II study including an open-label dose-escalation phase (Step 1) and a three-arm, controlled, double-masked, randomized extension phase (Step 2). In Cohorts 5 and 6 of Step 2, subjects and the designated study personnel will be masked to subject's dose assignment. Cohort 4 (untreated group) will be unmasked.
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Step 1 : SPVN06 dose 1
Participants will receive a single subretinal injection of SPVN06 Dose 1 on Day 0.
Group Type
EXPERIMENTAL
SPVN06
Intervention Type
DRUG
AAV-RdCVF-RdCVFL
Step 1 : SPVN06 dose 2
Participants will receive a single subretinal injection of SPVN06 Dose 2 on Day 0
Group Type
EXPERIMENTAL
SPVN06
Intervention Type
DRUG
AAV-RdCVF-RdCVFL
Step 1 : SPVN06 dose 3
Participants will receive a single subretinal injection of SPVN06 Dose 3 on Day 0
Group Type
EXPERIMENTAL
SPVN06
Intervention Type
DRUG
AAV-RdCVF-RdCVFL
Step 2 : SPVN06 Dose Recommended 1
Participants will receive a single subretinal injection of SPVN06 recommended dose 1 on Day 0
Group Type
EXPERIMENTAL
SPVN06
Intervention Type
DRUG
AAV-RdCVF-RdCVFL
Step 2 : SPVN06 Dose Recommended 2
Participants will receive a single subretinal injection of SPVN06 recommended dose 2 on Day 0
Group Type
EXPERIMENTAL
SPVN06
Intervention Type
DRUG
AAV-RdCVF-RdCVFL
Step 2 : Control group
Group Type
NO_INTERVENTION
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
SPVN06
AAV-RdCVF-RdCVFL
Intervention Type
DRUG
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Subjects will be eligible to participate in this study only if all the following criteria apply:
1. Able to give signed informed consent and comply with the requirements and restrictions listed in the informed consent form (ICF) and in the protocol.
2. Age ≥18 years at the time of ICF signature.
3. Subjects of either gender previously diagnosed with advanced RCD due to biallelic mutations in the rod cGMP phosphodiesterase 6 beta (PDE6B) or rod cGMP phosphodiesterase alpha (PDE6A) genes, or due to a monoallelic dominant mutation in the rhodopsin (RHO) gene. The genotyping results must be documented before the initiation of the Screening Visit. Subjects should be retested by the investigator if their genotyping tests were not performed within the 7 previous years, or if they were not performed by an accredited laboratory. In this case, the screening period can be prolonged for 2 additional weeks to allow time to generate genotyping results.
4. Advanced stage is defined as a stage of the natural history of the disease where both distance visual acuity and visual field are affected in both eyes. Substages within the advanced stage are defined as follows (monocular measurements, horizontal axis of isopter III4e for the visual field):
* Severe stage is defined by both a BCVA below or equal to 20/200 and above or equal to 20/800, and a visual field below or equal to 20 degrees (subjects of Cohorts 1 to 3)
* Intermediate stage is defined by both a BCVA below or equal to 20/40 and above 20/200, and a visual field below or equal to 20 degrees (subjects of Cohorts 4 to 6)
5. For subjects with severe advanced RCD enrolled in Step 1 only, the difference in visual acuity between the two eyes of a given subject should be equal to or below 0.3 logarithm of the minimal angle (LogMAR) (≤3 ETDRS lines), with a tolerance margin of 3 ETDRS letters.
6. Clinical diagnosis of RCD based on past medical and family history, mid-peripheral visual field dysfunction, photopsia, night blindness (nyctalopia), and fundoscopic appearance (including but not restricted to bone spicule pigmentation, attenuation of the retinal vessels, and waxy pallor of the optic nerve).
7. Diagnosis of RCD is confirmed on prior full-field ERG (any previously performed ERG is acceptable).
8. Documented preservation of cone inner and outer segments considered good enough by the investigator for the subject to be included in the study.
9. Negative serum pregnancy test for women of childbearing potential (please refer to Schedule of Assessments for details).
10. Women of childbearing potential (WOCBP) and men and/or their partner(s) of childbearing potential must agree to use a highly effective contraceptive method. This applies to the time period between ICF signature and 12 months after SPVN06 subretinal injection SRI (i.e., no longer applicable to subjects of Cohort 4 after randomization). The definition of highly effective contraceptive methods follows CTFG recommendations. Highly effective contraceptive methods are limited to:
* Combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation:
* Oral
* Intravaginal
* Transdermal
* Progestogen-only hormonal contraception associated with inhibition of ovulation:
* Oral
* Injectable
* Implantable
* Intrauterine device (IUD)
* Intrauterine hormone-releasing system (IUS)
* Bilateral tubal occlusion
* Vasectomized partner
* Sexual abstinence
11. Subjects must be affiliated to a health security system, if they are included in a clinical site based in France (per law).
12. No out-of-range values for clinical laboratory tests, however, if outside, must be considered as non-clinically relevant by the investigator using a multidisciplinary approach and compatible with a participation in the clinical study.
13. 12-lead electrocardiogram within normal limits, however, when outside, must be documented by the investigator using a multidisciplinary approach as not clinically relevant and compatible with a participation in the clinical study. Nota bene: This criterion of eligibility is only applicable to subjects assigned to a treatment cohort (Cohorts 1, 2, 3, 5, or 6), and is not required to authorize randomization in Step 2.
14. Physical examination without any clinical findings of clinical relevance (per medical/anesthesia staffs judgment) that could compromise participation in the clinical study or could affect the collection and/or evaluation of the study parameters. The findings of clinical relevance considered as contraindications to SPVN06 treatment include, but are not limited to, pulmonary pathology such as COPD, asthma, cardiac conditions such as congestive heart failure or valve disease, renal issues such as renal insufficiency and endocrine issues such as diabetes.
4. Subjects with systemic disease or other pathology not related to their diagnosis of RCD, and whose symptoms or associated treatments may affect vision, for example cancers or pathology of the central nervous system.
5. Subjects with narrow irido-corneal angles or any other medical situation contraindicating pupillary dilation.
6. Subjects known to be allergic to any of the delivery vehicle constituents or to any other drugs planned to be used during the clinical study.
7. Subjects with known allergies to corticosteroids, or who will be unable to tolerate the corticosteroid regimen as described in the protocol
8. Subjects with systemic disease or other medical or psychiatric conditions that preclude safe participation in the study.
9. Subjects receiving immunosuppressive therapies, other than the immune modulating regimen described in this protocol, or any other therapy known to influence the immune system including but not limited to steroid implants, cytostatics, interferons, tumor necrosis factor (TNF)-binding proteins, drugs acting on immunophilins, or antibodies with known impact on the immune system.
10. Subjects of reproductive potential unwilling to use effective contraception starting right after ICF signature and for 12 months after SPVN06 SRI (i.e., no longer applicable to subjects of Cohort 4 after randomization).
11. Subjects who are pregnant or breastfeeding.
12. Subjects who are unwilling or unable (based on the investigator's judgment) to comply with the study protocol.
13. Subjects with any condition that would not allow them to complete follow-up examinations during the study and, in the opinion of the investigator, would make them unsuitable for the study.
14. Subjects positive for human immunodeficiency virus (HIV) or any other systemic immunocompromising disease.
15. Subjects who have undergone, within 6 months before inclusion, any significant ocular surgery (per investigator's judgment) that could interfere with the evaluation of SPVN06 study objectives.
16. Presence of eye disorders that could interfere with the assessment of visual acuity and/or any other ocular assessments, including SD-OCT, during the study.
17. Presence of any systemic or ocular diseases, other than non-syndromic retinitis pigmentosa (RP), that can cause vision loss.
18. Prior vitrectomy or vitreomacular surgery.
19. Presence of vitreomacular adhesion or traction, epiretinal membrane macular pucker or macular hole, evident by ophthalmoscopy and/or SD-OCT examinations and assessed by the investigator to significantly affect central vision.
20. Current evidence of retinal detachment assessed by the investigator to significantly affect central vision.
21. Active ocular inflammation or recurrent history of idiopathic or autoimmune-associated uveitis.
22. Subjects with presence of any suspected or active ocular or periocular infection (conjunctivitis, keratitis, scleritis, endophthalmitis).
23. Subjects with history of glaucoma.
24. Subjects with uncontrolled intraocular pressure (IOP).
25. Subjects with active cancer or currently receiving any therapy for cancer treatment.
26. Subjects with any history of ocular malignancy.
27. Subjects with a clinically significant cardiac disease on routine clinical examination (history, physical examination), or known congestive heart failure, myocardial infarction, clinically significant valvular heart disease, clinically significant cardiac rhythm or conduction abnormalities.
28. Subjects with unstable/uncontrolled hypertension, defined by national recommendations.
29. Subjects with pulmonary dysfunction or severe obstructive pulmonary disease.
30. Subjects with active tuberculosis.
31. Subjects with liver or renal insufficiency.
32. Subjects with unstable endocrine disease, including unstable diabetes or thyroid disease.
33. Subjects with active Hepatitis B or Hepatitis C.
34. Subjects with clinically active infection of herpetic diseases, including herpes simplex virus, varicella zoster virus (VZV), cytomegalovirus (CMV) or EBV.
35. Subjects with known history of ocular infection with herpes simplex virus.
36. Subjects with active (extraocular) infection (requiring or not the prolonged or chronic use of antimicrobial agents).
37. Immunocompromised subjects with previous solid organ or bone marrow transplant.
38. Subjects who receive a live vaccine less than 4 weeks prior to SPVN06 injection
39. Subjects who were infected by COVID-19 less than 2 weeks prior to SPVN06 injection.
40. Subjects who have recently received (less than 4 weeks) or plan to receive a COVID-19 vaccination.
41. Incapacitated subjects, as defined by national laws.
1. Able to give signed informed consent and comply with the requirements and restrictions listed in the informed consent form (ICF) and in the protocol.
2. Age ≥18 years at the time of ICF signature.
3. Subjects of either gender previously diagnosed with advanced RCD due to biallelic mutations in the rod cGMP phosphodiesterase 6 beta (PDE6B) or rod cGMP phosphodiesterase alpha (PDE6A) genes, or due to a monoallelic dominant mutation in the rhodopsin (RHO) gene. The genotyping results must be documented before the initiation of the Screening Visit. Subjects should be retested by the investigator if their genotyping tests were not performed within the 7 previous years, or if they were not performed by an accredited laboratory. In this case, the screening period can be prolonged for 2 additional weeks to allow time to generate genotyping results.
4. Advanced stage is defined as a stage of the natural history of the disease where both distance visual acuity and visual field are affected in both eyes. Substages within the advanced stage are defined as follows (monocular measurements, horizontal axis of isopter III4e for the visual field):
* Severe stage is defined by both a BCVA below or equal to 20/200 and above or equal to 20/800, and a visual field below or equal to 20 degrees (subjects of Cohorts 1 to 3)
* Intermediate stage is defined by both a BCVA below or equal to 20/40 and above 20/200, and a visual field below or equal to 20 degrees (subjects of Cohorts 4 to 6)
5. For subjects with severe advanced RCD enrolled in Step 1 only, the difference in visual acuity between the two eyes of a given subject should be equal to or below 0.3 logarithm of the minimal angle (LogMAR) (≤3 ETDRS lines), with a tolerance margin of 3 ETDRS letters.
6. Clinical diagnosis of RCD based on past medical and family history, mid-peripheral visual field dysfunction, photopsia, night blindness (nyctalopia), and fundoscopic appearance (including but not restricted to bone spicule pigmentation, attenuation of the retinal vessels, and waxy pallor of the optic nerve).
7. Diagnosis of RCD is confirmed on prior full-field ERG (any previously performed ERG is acceptable).
8. Documented preservation of cone inner and outer segments considered good enough by the investigator for the subject to be included in the study.
9. Negative serum pregnancy test for women of childbearing potential (please refer to Schedule of Assessments for details).
10. Women of childbearing potential (WOCBP) and men and/or their partner(s) of childbearing potential must agree to use a highly effective contraceptive method. This applies to the time period between ICF signature and 12 months after SPVN06 subretinal injection SRI (i.e., no longer applicable to subjects of Cohort 4 after randomization). The definition of highly effective contraceptive methods follows CTFG recommendations. Highly effective contraceptive methods are limited to:
* Combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation:
* Oral
* Intravaginal
* Transdermal
* Progestogen-only hormonal contraception associated with inhibition of ovulation:
* Oral
* Injectable
* Implantable
* Intrauterine device (IUD)
* Intrauterine hormone-releasing system (IUS)
* Bilateral tubal occlusion
* Vasectomized partner
* Sexual abstinence
11. Subjects must be affiliated to a health security system, if they are included in a clinical site based in France (per law).
12. No out-of-range values for clinical laboratory tests, however, if outside, must be considered as non-clinically relevant by the investigator using a multidisciplinary approach and compatible with a participation in the clinical study.
13. 12-lead electrocardiogram within normal limits, however, when outside, must be documented by the investigator using a multidisciplinary approach as not clinically relevant and compatible with a participation in the clinical study. Nota bene: This criterion of eligibility is only applicable to subjects assigned to a treatment cohort (Cohorts 1, 2, 3, 5, or 6), and is not required to authorize randomization in Step 2.
14. Physical examination without any clinical findings of clinical relevance (per medical/anesthesia staffs judgment) that could compromise participation in the clinical study or could affect the collection and/or evaluation of the study parameters. The findings of clinical relevance considered as contraindications to SPVN06 treatment include, but are not limited to, pulmonary pathology such as COPD, asthma, cardiac conditions such as congestive heart failure or valve disease, renal issues such as renal insufficiency and endocrine issues such as diabetes.
4. Subjects with systemic disease or other pathology not related to their diagnosis of RCD, and whose symptoms or associated treatments may affect vision, for example cancers or pathology of the central nervous system.
5. Subjects with narrow irido-corneal angles or any other medical situation contraindicating pupillary dilation.
6. Subjects known to be allergic to any of the delivery vehicle constituents or to any other drugs planned to be used during the clinical study.
7. Subjects with known allergies to corticosteroids, or who will be unable to tolerate the corticosteroid regimen as described in the protocol
8. Subjects with systemic disease or other medical or psychiatric conditions that preclude safe participation in the study.
9. Subjects receiving immunosuppressive therapies, other than the immune modulating regimen described in this protocol, or any other therapy known to influence the immune system including but not limited to steroid implants, cytostatics, interferons, tumor necrosis factor (TNF)-binding proteins, drugs acting on immunophilins, or antibodies with known impact on the immune system.
10. Subjects of reproductive potential unwilling to use effective contraception starting right after ICF signature and for 12 months after SPVN06 SRI (i.e., no longer applicable to subjects of Cohort 4 after randomization).
11. Subjects who are pregnant or breastfeeding.
12. Subjects who are unwilling or unable (based on the investigator's judgment) to comply with the study protocol.
13. Subjects with any condition that would not allow them to complete follow-up examinations during the study and, in the opinion of the investigator, would make them unsuitable for the study.
14. Subjects positive for human immunodeficiency virus (HIV) or any other systemic immunocompromising disease.
15. Subjects who have undergone, within 6 months before inclusion, any significant ocular surgery (per investigator's judgment) that could interfere with the evaluation of SPVN06 study objectives.
16. Presence of eye disorders that could interfere with the assessment of visual acuity and/or any other ocular assessments, including SD-OCT, during the study.
17. Presence of any systemic or ocular diseases, other than non-syndromic retinitis pigmentosa (RP), that can cause vision loss.
18. Prior vitrectomy or vitreomacular surgery.
19. Presence of vitreomacular adhesion or traction, epiretinal membrane macular pucker or macular hole, evident by ophthalmoscopy and/or SD-OCT examinations and assessed by the investigator to significantly affect central vision.
20. Current evidence of retinal detachment assessed by the investigator to significantly affect central vision.
21. Active ocular inflammation or recurrent history of idiopathic or autoimmune-associated uveitis.
22. Subjects with presence of any suspected or active ocular or periocular infection (conjunctivitis, keratitis, scleritis, endophthalmitis).
23. Subjects with history of glaucoma.
24. Subjects with uncontrolled intraocular pressure (IOP).
25. Subjects with active cancer or currently receiving any therapy for cancer treatment.
26. Subjects with any history of ocular malignancy.
27. Subjects with a clinically significant cardiac disease on routine clinical examination (history, physical examination), or known congestive heart failure, myocardial infarction, clinically significant valvular heart disease, clinically significant cardiac rhythm or conduction abnormalities.
28. Subjects with unstable/uncontrolled hypertension, defined by national recommendations.
29. Subjects with pulmonary dysfunction or severe obstructive pulmonary disease.
30. Subjects with active tuberculosis.
31. Subjects with liver or renal insufficiency.
32. Subjects with unstable endocrine disease, including unstable diabetes or thyroid disease.
33. Subjects with active Hepatitis B or Hepatitis C.
34. Subjects with clinically active infection of herpetic diseases, including herpes simplex virus, varicella zoster virus (VZV), cytomegalovirus (CMV) or EBV.
35. Subjects with known history of ocular infection with herpes simplex virus.
36. Subjects with active (extraocular) infection (requiring or not the prolonged or chronic use of antimicrobial agents).
37. Immunocompromised subjects with previous solid organ or bone marrow transplant.
38. Subjects who receive a live vaccine less than 4 weeks prior to SPVN06 injection
39. Subjects who were infected by COVID-19 less than 2 weeks prior to SPVN06 injection.
40. Subjects who have recently received (less than 4 weeks) or plan to receive a COVID-19 vaccination.
41. Incapacitated subjects, as defined by national laws.
Exclusion Criteria
Subjects are not eligible to participate in this study if any of the following criteria apply:
1. Subjects with prior administration of any gene therapy or any previous treatment with stem cell therapy for ocular or non-ocular disease.
2. Subjects participating in another clinical trial and receiving an investigational medicinal product (IMP) within 5 half-lives or 90 days prior to the injection of SPVN06.
1. Subjects with prior administration of any gene therapy or any previous treatment with stem cell therapy for ocular or non-ocular disease.
2. Subjects participating in another clinical trial and receiving an investigational medicinal product (IMP) within 5 half-lives or 90 days prior to the injection of SPVN06.
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
SparingVision
INDUSTRY
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Bascom Palmer Eye Institute/University of Miami
Miami, Florida, United States
Site Status
RECRUITING
Mass Eye and Ear
Boston, Massachusetts, United States
Site Status
RECRUITING
Casey Eye Institute
Portland, Oregon, United States
Site Status
RECRUITING
UPMC Eye Center
Pittsburgh, Pennsylvania, United States
Site Status
RECRUITING
Retina Foundation of the Southwest
Dallas, Texas, United States
Site Status
RECRUITING
CHNO XV-XX Paris - CIC 1423
Paris, , France
Site Status
RECRUITING
Countries
Review the countries where the study has at least one active or historical site.
United States
France
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Medical Director
Role: CONTACT
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Marie M, Churet L, Gautron AS, Farjo R, Mizuyoshi K, Stevenson V, Khabou H, Leveillard T, Sahel JA, Lorget F. Preclinical safety and biodistribution of SPVN06, a novel gene- and mutation-independent gene therapy for rod-cone dystrophies. Gene Ther. 2025 Aug 4. doi: 10.1038/s41434-025-00556-3. Online ahead of print.
Reference Type
DERIVED
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SPVN06-CLIN-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Efficacy and Safety Study of CNTO 2476 in Participants With Visual Acuity Impairment Associated With Geographic Atrophy (GA) Secondary to Age Related Macular Degeneration (AMD)
NCT02895815
WITHDRAWN
PHASE2
A Dose Ranging Study to Evaluate the Safety and Potential Efficacy of rhNGF in Patients With Retinitis Pigmentosa (RP)
NCT02110225
COMPLETED
PHASE1/PHASE2
A Study to Evaluate the Safety of CNTO 2476 in Patients With Advanced Retinitis Pigmentosa
NCT00458575
TERMINATED
PHASE1
Sub-retinal Transplantation of hESC Derived RPE(MA09-hRPE)Cells in Patients With Stargardt's Macular Dystrophy
NCT01345006
COMPLETED
PHASE1/PHASE2
Efficacy, Safety And Tolerability Study Of RN6G In Subjects With Geographic Atrophy Secondary to Age-related Macular Degeneration
NCT01577381
TERMINATED
PHASE2
CNS10-NPC for the Treatment of RP
NCT04284293
ACTIVE_NOT_RECRUITING
PHASE1
UGX202 Injection in Patients With Advanced Retinitis Pigmentosa
NCT07311863
NOT_YET_RECRUITING
EARLY_PHASE1
A Study to Investigate the Safety of DSP-3077 After a Unilateral Eye Injection in Male and Female Participants 18 Years of Age or Older With Retinitis Pigmentosa
NCT06891885
RECRUITING
PHASE1/PHASE2
A Phase II Study of STSP-0902 Ophthalmic Solution in Patients With Neurotrophic Keratitis
NCT06975748
RECRUITING
PHASE2
Safety And Tolerability Study Of RN6G In Subjects With Advanced Dry, Age-Related Macular Degeneration Including Geographic Atrophy
NCT01003691
COMPLETED
PHASE1
A Phase 1/2, First-in-Human Dose Escalation/Expansion Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of a Subretinal Injection of SB-007 in Subjects With Stargardt Disease (STGD1)
NCT06942572
RECRUITING
PHASE1/PHASE2
Dose-escalation Study to Evaluate the Safety and Tolerability of GS030 in Subjects With Retinitis Pigmentosa
NCT03326336
ACTIVE_NOT_RECRUITING
PHASE1/PHASE2
Dose Escalation Study to Evaluate the Safety/Tolerability and Efficacy of EA-2353 in Subjects With Retinitis Pigmentosa
NCT05392751
TERMINATED
PHASE1/PHASE2
Prospective, Randomized, Sham-controlled, Dose-finding I/II Trial of Safety and Efficacy of Modified Optogenetic Gene Therapy (ZM-02 Injection)
NCT07282457
NOT_YET_RECRUITING
PHASE1/PHASE2
Safety and Tolerability Study of RO7171009 in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)
NCT03295877
COMPLETED
PHASE1
A Study of Encapsulated Cell Technology (ECT) Implant for Participants With Early Stage Retinitis Pigmentosa
NCT00447980
COMPLETED
PHASE2
Intravitreal Injections of rhuFab V2 in Combination With Visudyne in Subjects With Age Related Macular Degeneration (AMD)
NCT00056823
COMPLETED
PHASE1/PHASE2
A Patient Registry Study for Patients Treated With Voretigene Neparvovec in US
NCT03597399
COMPLETED
A Study Assessing the Safety and Efficacy of Multiple Intravitreal KH902 in Patients With CNV Due to AMD
NCT01242254
COMPLETED
PHASE1/PHASE2
A Phase IIb Randomized, Multicenter Trial of Subretinal CPCB-RPE1 in Advanced Dry AMD (Geographic Atrophy)
NCT06557460
RECRUITING
PHASE2
Gene Therapy for Gyrate Atrophy
NCT00001735
COMPLETED
PHASE1
Evaluating RXI-109 to Reduce the Progression of Subretinal Fibrosis in Subjects With NVAMD
NCT02599064
UNKNOWN
PHASE1/PHASE2
A Phase 3 Study Of OCU400 Gene Therapy for the Treatment Of Retinitis Pigmentosa
NCT06388200
RECRUITING
PHASE3
Safety and Tolerability of Intravitreal Administration of VG901 in Patients With Retinitis Pigmentosa Due to Mutations in the CNGA1 Gene
NCT06291935
RECRUITING
PHASE1
REP1 Gene Replacement Therapy for Choroideremia
NCT02407678
COMPLETED
PHASE2